TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01949142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Description: Single, intratympanic injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Simulated single, intratympanic injection
Study: NCT01796275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core intervention program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core intervention program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster session

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control only (Tea gathering)
Study: NCT02283476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar continuous intravenous infusion
Description: Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostar routine intravenous infusion
Description: Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
Study: NCT00565604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Catheter Delivery
Description: For treating incompetent perforator veins of the lower extremities
Study: NCT03185494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/22-CAR vector-transduced T cells
Description: genetically engineered lymphocyte therapy
Study: NCT02584374

Intervention type: OTHER
Intervention: Venography with balloon occlusion test
Description: First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.

Intervention type: OTHER
Intervention: Venography with balloon occlusion test
Description: First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
Study: NCT01709864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
Study: NCT04067596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epiphysiodesis
Description: The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase.
Study: NCT02283476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
Study: NCT04542278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: used to reduce inflammation
Study: NCT01832883

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.
Study: NCT00615810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla
Description: Open label once daily for oral administration to be taken on an empty stomach

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kivexa plus Sustiva
Description: Open label once daily for oral administration
Study: NCT03454386

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management and Resilience Training Program
Description: This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Management Stress Reduction Program
Description: Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
Study: NCT02849210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot with Olea europaea pollen extract
Description: Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
Study: NCT00703326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab (IMC-1121B)
Description: Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
Study: NCT03115593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blind biopsy with a pipette
Description: Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted biopsy using hysteroscopy
Description: During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
Study: NCT02379455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive drug review
Description: 1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
Study: NCT04037800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SFUR-RARP
Description: Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard RARP
Description: Robotic-assisted radical prostatectomy with conventional RARP procedures.
Study: NCT04581018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health supplements
Description: 28 days of health supplements (synbiotic), 4g daily
Study: NCT03734809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg every 3 weeks infusion
Study: NCT04520906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
Study: NCT02157571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Description: 600 mg/tablet, oral administration of a single tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: 500 mg/tablet, oral administration of a tablet daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Placebo
Description: Placebo of levofloxacin hydrochloride tablet, without active components.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prulifloxacin placebo
Description: Placebo of prulifloxacin film-coated tablet without active components.
Study: NCT01473017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based Guided Self-Help
Description: CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
Study: NCT01417104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 150 mg/300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg/300mg
Study: NCT01293942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab
Description: IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
Study: NCT03889847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation with silicone double lumen tube
Description: Fibreoptic intubation with silicone double lumen tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation with PVC double lumen tube
Description: Fibreoptic intubation with PVC double lumen tube
Study: NCT01564277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasburicase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasburicase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: Given PO
Study: NCT01851551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome Injection plus rituximab
Study: NCT00246090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 1.4 mg/m\^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
Study: NCT01896622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Impact on dabigatran PK/PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Impact on dabigatran PK/PD
Study: NCT01589159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Drug:capecitabine 700mg/m2, twice daily on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 30mg/m2, once daily on days 1-7.
Study: NCT03780777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Hazard Removal
Description: Removal of home barriers or hazards
Study: NCT04937322

Intervention type: PROCEDURE
Intervention: Interventional Endoscopy procedures
Description: • All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations and stent insertion(s) for pancreatico-biliary disorders.
Study: NCT02588872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma (PRP)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Study: NCT01552759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postprandial responses
Description: Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postprandial responses
Description: Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postprandial responses
Description: Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Subjects are presented with an ad libitum buffet meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Subjects are presented with an ad libitum buffet meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Subjects are presented with an ad libitum buffet meal.
Study: NCT04089189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: IMP4297 100mg PO QD
Study: NCT05680753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy
Study: NCT00916708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive/Low-Risk follow up (IA G1; IA G2)
Description: - First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months~- Since the third to the fifth year of FU: clinical visit\* every 6 months; Pap test every 12 months~\* clinical visit with gynecological exploration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive/High-Risk follow up (≥ IA G3)
Description: - First 3 years of FU since the end of primary treatment: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months~- In the fourth and fifth years of FU: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months~\* clinical visit with gynecological exploration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimalist/Low-Risk follow up (IA G1; IA G2)
Description: - First 5 years of FU since the end of primary treatment: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimalist/High-Risk follow up (≥ IA G3)
Description: - First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; chest, abdomen, pelvis CT every 12 months~- Since the third to the fifth year of surveillance: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration
Study: NCT03053453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Surgery
Description: TKA under standard of care spinal surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verasense Knee System device
Description: Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
Study: NCT01243788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/Fluticasone Propionate
Description: Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
Study: NCT03332784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 Placebo Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 Placebo Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 Placebo Intravenous Infusion
Study: NCT02985359

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutributter
Description: Daily 20g Nutributter provided to children 6 to 24 month of age

Intervention type: BEHAVIORAL
Intervention: Social Behavioral Change Communication (SBCC)
Description: Social Behavioral Change Communication (SBCC) activity focused on improving infant and young child feeding (IYCF) practices and water, sanitation, and hygiene (WASH) behaviors through community groups.
Study: NCT04489277

Intervention type: DEVICE
Intervention: Endovascular Arch Procedures
Description: Endovascular Arch Procedures (TEVAR, Branch endografts, Fenestrated endografts)

Intervention type: DEVICE
Intervention: Endovascular Arch Procedures
Description: Endovascular Arch Procedures (TEVAR, Branch endografts, Fenestrated endografts)
Study: NCT01987492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
Study: NCT02933086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercises for lumbar stabilization
Description: The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
Study: NCT01328353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth plus aprn triage
Description: aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth plus aprn triage
Description: aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
Study: NCT01005797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589), Sorafenib
Description: Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589), Sorafenib
Description: Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589), Sorafenib
Description: Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
Study: NCT04438720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Nifedipine Tablets 30 mg
Description: The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.